icon-folder.gif   Conference Reports for NaTaP  
 
  EASL - The International Liver Congress 2015
50th annual Meeting of the European
association for the Study of the Liver
Vienna, austria áapril 22-26
Back grey_arrow_rt.gif
 
 
 
BMS at EASL
 
 
  from Jules: At EASL results were reported for ALLY-1/2/3, the phase 3 clinical trials program for daclatasvir, approval by the FDA for Gt3 is expected around August, PDUFA date [http://www.natap.org/2015/HCV/031615_07.htm]. As well below are a number of European cohort studies examining daclatasvir/sofosbuvir. Of note is the French liver transplant study below from Audrey Coilly and the Compassionate Use Program results.
 
EASL: Daclatasvir, Sofosbuvir, and Ribavirin Combination for HCV Patients with Advanced Cirrhosis or Post-transplant Recurrence: ALLY-1 Phase 3 Study - (04/28/15)
 
EASL: Daclatasvir Plus Sofosbuvir for Treatment of HCV Genotypes 1-4 in HIV-HCV Coinfection: The ALLY-2 Study - (04/28/15)
 
EASL: On-Treatment HCV RNA as a Predictor of Sustained Virologic Response in HCV Genotype 3-Infected Patients Treated With Daclatasvir and Sofosbuvir: A Subanalysis of the Phase 3 ALLY-3 Study - (04/28/15)
 
EASL: ALL-ORAL 12-WEEK COMBINATION TREATMENT WITH DACLATASVIR AND SOFOSBUVIR IN TREATMENT-EXPERIENCED PATIENTS INFECTED WITH HCV GENOTYPE 3: A SUBANALYSIS OF THE ALLY-3 PHASE 3 STUDY - (04/28/15)
 
APASL: All-Oral 12-Week Combination Treatment With Daclatasvir and Sofosbuvir in Patients Infected With HCV Genotype 3: ALLY-3 Phase 3 Study - (03/18/15)
 
published - All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study - (04/15/15)
 
---------------------------
 
EASL: The association of Sofosbuvir and Daclatasvir for treating severe recurrence of HCV infection after liver transplantation - (04/27/15)
 
EASL: Daclatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of HCV in Patients With Severe Liver Disease: Interim Results of a Multicenter Compassionate Use Program - (04/29/15)
 
EASL: Simeprevir plus daclatasvir and sofosbuvir in treatment-na´ve and treatment-experienced patients with chronic hepatitis C virus genotype 1 or 4 infection and decompensated liver disease: interim results from the Phase II IMPACT study - (04/24/15)
 
EASL: On-treatment virologic response and tolerability of simeprevir, daclatasvir and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation (OLT): interim data from the Phase II SATURN study - (04/23/15)
 
---------------------
 
Cohort Studies
 
EASL: Daclatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of HCV in Patients With Severe Liver Disease: Interim Results of a Multicenter Compassionate Use Program - (04/29/15)
 
EASL: Treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks sofosbuvir and NS5A inhibitors with/without ribavirin is effective in HCV Genotypes 1 and 3 - (04/24/15)
 
EASL: SAFETY AND EFFICACY OF THE COMBINATION DACLATASVIR-SOFOSBUVIR IN HCV GENOTYPE 1-MONO-INFECTED PATIENTS FROM THE FRENCH OBSERVATIONAL COHORT ANRS CO22 HEPATHER - (04/27/15)
 
EASL: DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HCV GENOTYPE 3 INFECTION: INTERIM ANALYSIS OF A FRENCH MULTICENTER COMPASSIONATE USE PROGRAM - (04/24/15)
 
EASL: DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HIV-HCV COINFECTION: INTERIM ANALYSIS OF A FRENCH MULTICENTER COMPASSIONATE USE PROGRAM - (04/24/15)
 
EASL: Safety and efficacy of all-oral DAA regimens in HIV-HCV coinfected cirrhotic patients from the prospective ANRS CO13 - HEPAVIH cohort - (04/28/15)
 
EASL: Efficacy of the oral Sofosbuvir-based combination in HCV genotype 4-monoinfected patients from the French observational cohort ANRS CO22 HEPATHER - (04/28/15)
 
---------------------
 
EASL: Effect of Baseline Factors on Response to the Fixed-Dose Combination Of Daclatasvir, Asunaprevir and Beclabuvir in Non-Cirrhotic Patients with HCV Genotype 1 Infection - (05/05/15)
 
EASL: Effect of Baseline Factors on Response to the Fixed-Dose Combination of Daclatasvir, Asunaprevir, and Beclabuvir, With or Without Ribavirin, in Patients With HCV Genotype 1 Infection and Cirrhosis - (05/05/15)
 
EASL: The Pharmacokinetics of Beclabuvir (BMS-791325) When Administered in Combination With Daclatasvir and Asunaprevir in Treatment-naive Patients With or Without Cirrhosis Infected With HCV Genotype 1 - (05/05/15)
 
EASL: The Effect of Renal Impairment on Multiple-dose Pharmacokinetics of the Fixed-dose Combination of Daclatasvir/Asunaprevir/Beclabuvir - (05/05/15)
 
published - Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection - (05/06/15)
 
published - Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis - (05/06/15)
 
EASL: Evaluation of Drug-Drug Interactions Between the Fixed-Dose Combination of Daclatasvir/Asunaprevir/Beclabuvir and Methadone or Buprenorphine/Naloxone - (05/05/15)